Allspring Global Investments Holdings LLC Has $60.31 Million Position in Exelixis, Inc. $EXEL

Allspring Global Investments Holdings LLC lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 18.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,383,820 shares of the biotechnology company’s stock after buying an additional 216,048 shares during the period. Allspring Global Investments Holdings LLC owned about 0.52% of Exelixis worth $60,307,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Exelixis by 81.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares in the last quarter. Focus Partners Wealth increased its holdings in Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after buying an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. raised its position in Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC raised its position in Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after acquiring an additional 2,764 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In related news, Director Bob Oliver sold 30,250 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the completion of the sale, the director owned 21,120 shares of the company’s stock, valued at $925,267.20. This represents a 58.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Christopher J. Senner sold 34,278 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $43.00, for a total transaction of $1,473,954.00. Following the sale, the chief financial officer owned 1,042,579 shares in the company, valued at $44,830,897. The trade was a 3.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 362,849 shares of company stock valued at $15,917,463 in the last ninety days. Insiders own 2.82% of the company’s stock.

Exelixis Trading Up 2.7%

Shares of EXEL stock opened at $44.04 on Thursday. The stock has a market cap of $11.44 billion, a P/E ratio of 15.90, a price-to-earnings-growth ratio of 0.96 and a beta of 0.42. Exelixis, Inc. has a 1 year low of $32.38 and a 1 year high of $49.62. The stock has a 50 day simple moving average of $42.70 and a 200 day simple moving average of $42.05.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The firm had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company earned $0.55 EPS. Analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research analyst reports. Bank of America cut shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price on the stock. in a report on Monday, January 5th. Royal Bank Of Canada lowered their price target on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research report on Monday, March 2nd. Truist Financial upgraded Exelixis to a “strong-buy” rating in a research note on Wednesday, March 25th. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. Finally, Wells Fargo & Company boosted their target price on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Exelixis currently has a consensus rating of “Hold” and a consensus target price of $46.94.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.